Muscle Fiber Fragments for Improved Function of Rotator Cuff Musculature Following Rotator Cuff Repair

ConditionRotator Cuff
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-80
SponsorWake Forest University Health Sciences

About this trial

In this study, a chest muscle sample (biopsy) will be taken and the muscle fibers will be removed from the sample and made into smaller strands or fragments. During this same procedure, those muscle fiber fragments (MFFs) will then be injected directly into the supraspinatus muscle. Once injected, the MFFs will remain in the supraspinatus where Investigators believe the MFF will become part of the participants' existing muscle and provide increased muscle size and strength, improving function (rotator cuff strength and stability).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Males and females, ages 40 to 80 years

Unilateral Disease

< 1.5cm tear

Disqualifiers

Diabetes

Peripheral Neuropathy

Previous Shoulder Surgery

Pain Syndrome; cuff arthroplasty

Trial design

Design model

Single group

Treatments tested in this trial

  • Muscle Fiber Fragments (MFFs)

    Other intervention

    During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Muscle Fiber Fragments (MFF)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of Adverse Events

The incidence of adverse events will be documented in the areas of product related, biopsy procedure-related, and injection-related reporting for each group.

Time frame
6 months post surgery
2

Incidence of Adverse Events

The incidence of adverse events will be documented in the areas of product related, biopsy procedure-related, and injection-related reporting for each group.

Time frame
12 months post surgery

Secondary outcomes

1

Fat Free Muscle Volume

Fat-free muscle volume (total muscle volume minus % of fatty infiltration).

Time frame
Month 1, Month 6, and Month 12
2

Goutallier Score via MRI 1.5+ image analysis

Measured by MRI T1 Sagittal image at the Y position. Total score values 0- 4 (Grade 0 =normal muscle; Grade 1 =Muscle that contain some fatty streaks; Grade 2 = Fatty infiltration but more muscle than fat; Grade 3 = Equal amounts of fat and muscle; Grade 4 = More fat than muscle.) Lower values denotes better outcomes.

Time frame
12 weeks, 6 months, and 12 months post operatively
3

Constant Score

The constant score, a 0-100 point scale with 100 being Normal and Abnormal Side \>30 Poor, 21-30 Fair, 11-20 Good and \<11 Excellent will measure muscle recovery including strength and level of atrophy. Higher scores denote worse outcome measures.

Time frame
12 weeks, 6 months, and 12 months post operatively
4

ASES Shoulder Score

The ASES Shoulder Score (scale with a max of 100 which is normal function with no pain to minimum of 0 which is extreme pain) will measure muscle recovery. Higher scores denote better outcomes.

Time frame
12 weeks, 6 months, and 12 months post operatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.